Seeking Alpha

Biogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically...

Biogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically meaningful reductions" in relapses and brain lesions in patients with relapsing-remitting MS, data from two Phase III trials show. BG-12 also slowed the progress of the disease. The drug could be on track to become the third oral medicine for MS, as well as the safest and most effective. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs